Social Media Monitoring on Verzenio: Research and Study on Social Media Channels

Social Media Monitoring on Verzenio: Research and Study on Social Media Channels
Product Code: Social-media-monitoring
Availability: In Stock
Price: $2,999.00
Ex Tax: $2,999.00

Research Study Background

Eli Lilly  a new CDK4 & 6 inhibitor, Verzenio (abemaciclib) got US FDA approval on 17th September 2017  in combination with fulvestrant for women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) for advanced or metastatic breast cancer. Verzenio got marketing approval on the basis of MONARCH 2 Phase 3 Trial  and MONARCH 1 Phase 1 Trial where abemaciclib in combination with fulvestrant demonstrated a greater than 16-month median progression-free survival (PFS) in patients who progressed on endocrine therapy. Eli Lilly and Company was hoping for success of Verzenio in Lung Cancer patient because abemaciclib was failed to improve overall survival in a Phase 3 study testing it in lung cancer patients with a mutation. FDA approval of Verzenio illustrates devotion to determining, evolving, and providing innovative, foundational medicines that offers a meaningful difference to patients with Breast Cancer.

  1. Study was conducted to understand initial social media reaction on Verzenio where total 1,378 online posts were analysed by our subject matter experts.
  2. Study monitoring period was considered from 1st May – 28th Oct 2017.


  1. “HCPs, Patients, News, Advocacy groups and Caregivers sharing information on approval of Verzenio on various Social Media Channels
  2. Twitter followed by Forums and Mainstream having maximum volume of conversation.
  3. Positive posts where tracked around Verzenio benefits which says- Abemaciclib Improves PFS for HR+/HER2- Advanced Breast Cancer

Sentiment Analysis on Verzenio Drug Approval

Positive: Aliqopa approval was quoted as an Impressive breakthrough - "Thank goodness FDA approved a me too drug while not a single drug of this class has shown OS benefit in RCT" @vinayprasad82 on abemaciclib- MiteshBorad (HCP)

Neutral: Majority of healthcare practitioners and patients were either neutral or positive about the approval, efficacy and found sharing the information on social media platform- “The FDA approved Eli Lilly’s breast-cancer drug Verzenio!”- (Unidentified Individual)

Contact us for qualitative Social Media Listening reports and Pharma Social Media Monitoring Reports.

Socioinsider © 2021